abstract |
This invention provides an immunomodulator for use in the adjuvant, neoadjuvant or peri-adjuvant treatment, reduction, inhibition or control of cancer in patients that have undergone, or are intended to undergo, tumour resection surgery and/or one or more additional anticancer treatments or agents, preferably checkpoint inhibitor therapy. The invention also describes the use of one or more additional anticancer treatments or agents in the adjuvant, neoadjuvant or peri-adjuvant setting, as well as protocols and dosage regimens for use. |